Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non Operating Income (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Other Non Operating Income data on record, last reported at -$1.2 million in Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 196.49% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached -$5.4 million, down 90500.0%, while the annual FY2024 figure was -$2.1 million, 220.73% down from the prior year.
  • Other Non Operating Income reached -$1.2 million in Q3 2025 per TNXP's latest filing, down from -$97000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.2 million in Q3 2024 and bottomed at -$2.1 million in Q1 2025.
  • Average Other Non Operating Income over 3 years is -$336636.4, with a median of -$97000.0 recorded in 2025.
  • The widest YoY moves for Other Non Operating Income: up 596.51% in 2024, down 29800.0% in 2024.
  • A 3-year view of Other Non Operating Income shows it stood at $7000.0 in 2023, then tumbled by 29800.0% to -$2.1 million in 2024, then soared by 44.4% to -$1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$1.2 million in Q3 2025, -$97000.0 in Q2 2025, and -$2.1 million in Q1 2025.